

Currently released so far... 12404 / 251,287
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/10
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Adana
American Institute Taiwan, Taipei
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Barcelona
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chennai
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
Consulate Dubai
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Kolkata
Embassy Luxembourg
Embassy Luanda
Embassy London
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy La Paz
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Melbourne
Embassy Nicosia
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Naples
Consulate Naha
Embassy Pristina
Embassy Pretoria
Embassy Prague
Embassy Port Of Spain
Embassy Port Louis
Embassy Port Au Prince
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
USUN New York
USEU Brussels
US Office Almaty
US Mission Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
ASEC
AE
AF
AM
AR
AJ
AU
AORC
AG
AEMR
AMGT
APER
AGMT
AL
AFIN
AO
AMED
ADCO
AS
ABUD
ABLD
ASUP
ASECKFRDCVISKIRFPHUMSMIGEG
APECO
AID
AND
AMBASSADOR
AN
ARM
AY
AODE
AMG
ASCH
AMCHAMS
ARF
APCS
APEC
ASEAN
AGAO
ANET
ADPM
ACOA
ACABQ
AORL
AFFAIRS
ATRN
ACS
AFSI
AFSN
ADANA
ASIG
AA
AX
AUC
AC
AECL
AADP
AGRICULTURE
AMEX
ACAO
ACBAQ
AQ
AORG
ADM
AINF
AIT
ASEX
AGR
AROC
ATFN
AFGHANISTAN
AFU
AER
ALOW
AZ
AVERY
BA
BY
BU
BR
BE
BL
BO
BK
BM
BILAT
BH
BEXP
BF
BTIO
BC
BBSR
BMGT
BTIU
BG
BWC
BB
BD
BX
BP
BRUSSELS
BN
BIDEN
BT
CW
CH
CF
CD
CV
CVIS
CM
CE
CA
CJAN
CLINTON
CIA
CU
CASC
CI
CO
CACM
CDB
CN
CMGT
CS
CG
CBW
CIS
CR
CONDOLEEZZA
CPAS
CAN
CWC
CY
COUNTER
CDG
CL
CT
CIC
CIDA
CSW
CHR
CB
CODEL
COUNTERTERRORISM
CTR
COM
CICTE
CFED
CJUS
CKGR
CBSA
CEUDA
CARSON
CONS
CITEL
CLMT
CROS
CITT
CAC
CVR
CDC
CAPC
COPUOS
CBC
CBE
CARICOM
COE
COUNTRY
CLEARANCE
CACS
CTM
CNARC
ECON
EFIN
ETRD
EUN
EFIS
EG
ETTC
EZ
EPET
EAID
EAGR
ENRG
ECUN
EU
ELAB
ECPS
EAIR
EINV
ELTN
EWWT
EIND
EMIN
EI
ECIN
ENVR
ELECTIONS
EINVEFIN
EN
ES
ER
EC
EUC
EINT
EINVETC
ENGR
ET
EK
ENIV
ETRDEINVECINPGOVCS
ECONOMY
EAP
EFTA
EUR
EUMEM
EXIM
ERD
ENERG
EUREM
ESA
ERNG
EXTERNAL
EPA
EINVECONSENVCSJA
ECONOMICS
ELN
EINN
EFINECONCS
ENNP
EEPET
ETRDEINVTINTCS
ENVI
ETRO
ESENV
ECINECONCS
ECONOMIC
EAIDS
EDU
ETRA
ETRN
EFIM
EIAR
ETRC
EAIG
EXBS
EURN
ECIP
EREL
ECA
ENGY
ECONCS
ECONEFIN
ETC
ETRDECONWTOCS
EUNCH
EINDETRD
IR
IZ
IS
IAEA
INRB
IRAJ
IQ
IN
IT
IMO
INTERPOL
ICAO
IO
IC
ITALY
ITALIAN
IRAQI
ICTY
ID
IPR
IWC
ILC
INTELSAT
IL
IBRD
IMF
IA
IRC
ICRC
ILO
ITU
ITRA
IV
IDA
IAHRC
ICJ
ISRAELI
IRS
INMARSAT
ISRAEL
ISLAMISTS
INDO
IZPREL
ITPHUM
ITPGOV
ITF
IBET
IEFIN
INR
IACI
INTERNAL
IDP
IGAD
IEA
ICTR
IIP
INRA
INRO
IF
KJUS
KSCA
KNNP
KU
KCOR
KCRM
KDEM
KTFN
KHLS
KPAL
KWBG
KACT
KGHG
KPAO
KTIA
KIRF
KWMN
KS
KG
KZ
KN
KMDR
KISL
KSPR
KHIV
KPRP
KAWK
KR
KUNR
KDRG
KCIP
KGCC
KTIP
KSUM
KPKO
KVIR
KAWC
KPIN
KGIC
KRAD
KIPR
KOLY
KCFE
KMCA
KE
KV
KICC
KNPP
KBCT
KSEP
KFRD
KFLU
KVPR
KOCI
KBIO
KSTH
KMPI
KCRS
KOMC
KTBT
KPLS
KIRC
KREL
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KFLO
KBTS
KSTC
KTDB
KFSC
KX
KFTFN
KNEI
KIDE
KREC
KMRS
KICA
KPAONZ
KCGC
KSAF
KRGY
KCMR
KRVC
KVRP
KSEO
KCOM
KAID
KTEX
KNUC
KNAR
KNUP
KNNPMNUC
KLIG
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KCRCM
KHDP
KGIT
KNSD
KOMS
KWMM
KPAI
KHSA
KTLA
KO
KMFO
KRCM
KCSY
KSAC
KTRD
KPWR
KID
KWNM
KRIM
KPOA
KCHG
KOM
KSCI
KFIN
KMOC
KESS
KWAC
KMIG
KSEC
KIFR
KDEMAF
KPRV
KBTR
KERG
KTER
KDDG
KPAK
KRFD
KHUM
KDEV
KCFC
KWWMN
KWMNCS
KJUST
MARR
MOPS
MU
MTCRE
MNUC
MY
MASS
MCAP
MOPPS
MAR
MPOS
MO
ML
MR
MASC
MX
MD
MP
MA
MTRE
MIL
MCC
MZ
MK
MDC
MRCRE
MAPS
MV
MI
MEPN
MAPP
MEETINGS
MAS
MTS
MLS
MILI
MTCR
MG
MC
MARAD
MIK
MILITARY
MEDIA
MEPI
MUCN
MEPP
MT
MERCOSUR
MW
MASSMNUC
MQADHAFI
NZ
NATO
NG
NI
NO
NATIONAL
NU
NPT
NIPP
NL
NPG
NS
NA
NGO
NP
NSG
NDP
NAFTA
NR
NC
NH
NE
NSF
NPA
NK
NSSP
NRR
NATOPREL
NSC
NT
NW
NORAD
NEW
NV
NSFO
NAR
NASA
NZUS
OTRA
OVIP
OPRC
OPDC
OSCE
OAS
ODIP
OIIP
OFDP
OVP
OREP
OFFICIALS
OSAC
OEXC
OPCW
OIE
OIC
OFDA
OSCI
OPIC
OBSP
OECD
ON
OCII
OHUM
OES
OCS
OMIG
OPAD
OTR
PGOV
PREL
PHUM
PINR
PTER
PSOE
PINS
PARM
PK
PBTS
PEPR
PM
POLITICAL
PARTIES
PREF
PBIO
PROP
PA
PSI
PINT
PO
PKFK
PL
PAK
PE
POLITICS
PINL
POL
PHSA
PU
PF
POV
PFOR
PHALANAGE
PARTY
PARMS
PRGOV
PNAT
POLINT
PRAM
PMAR
PG
PAO
PROG
PRELP
PPA
PCUL
PSEPC
PSA
PREO
PAHO
PGIV
PREFA
PALESTINIAN
PAIGH
POSTS
PTBS
PGOVLO
PORG
PGOVE
PLN
PINF
PAS
PUNE
POLICY
PDEM
PDOV
PCI
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PBT
PHUMPGOV
PMIL
PNG
PP
PS
PHUH
PECON
POGOV
PY
PHUMPREL
PHUS
PRL
PGOC
PNR
PGGV
PROV
PTERE
PGOF
PHUMBA
PEL
RS
RU
RW
REGION
RP
RICE
ROBERT
RSP
RUPREL
RM
RO
RCMP
RSO
RELATIONS
REACTION
REPORT
RIGHTS
ROOD
RF
RFE
RIGHTSPOLMIL
SP
SA
SY
SF
SYR
SENV
SCUL
SOCI
SNAR
SO
SU
SG
STEINBERG
SHUM
SW
SMIG
SR
SZ
SIPRS
SI
SAARC
SPCE
SARS
SN
SYRIA
SANC
SL
SCRS
SC
SENVKGHG
SAN
SNARCS
SHI
SWE
SNARIZ
SIPDIS
SEN
SNARN
SPCVIS
SEVN
SSA
SH
SOFA
SK
ST
TPHY
TU
TRGY
TI
TX
TS
TW
TC
TFIN
TD
TSPA
TH
TT
TIP
TBIO
TSPL
TZ
TERRORISM
TRSY
TN
THPY
TINT
TF
TL
TV
TK
TO
TP
TURKEY
TNGD
TBID
TAGS
TR
UP
US
UNSC
UK
UZ
UE
UNESCO
UV
UNGA
UN
UNMIK
UNO
UY
UAE
UNEP
UG
UNHCR
UNHRC
USUN
UNAUS
USTR
USNC
USOAS
UNCHR
UNCSD
UNDP
USEU
USPS
UNDC
UNDESCO
UNCHC
UNFICYP
UNC
UNODC
UNPUOS
UNCND
UNICEF
UNCHS
UNVIE
USAID
UNIDROIT
Browse by classification
Community resources
courage is contagious
Viewing cable 09BRASILIA1338, BRAZIL IPR UPDATE: PHARMACEUTICAL SECTOR
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #09BRASILIA1338.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
09BRASILIA1338 | 2009-11-20 13:01 | 2010-12-16 06:06 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Brasilia |
VZCZCXRO4128
PP RUEHRG
DE RUEHBR #1338/01 3241351
ZNR UUUUU ZZH
P 201351Z NOV 09
FM AMEMBASSY BRASILIA
TO RUEHC/SECSTATE WASHDC PRIORITY 5389
RUCPDOC/DEPT OF COMMERCE WASHDC
INFO RUEHSO/AMCONSUL SAO PAULO 0085
RUEHRI/AMCONSUL RIO DE JANEIRO 0041
RUEHRG/AMCONSUL RECIFE 0113
RUEHNE/AMEMBASSY NEW DELHI 0612
RUCPDOC/USDOC WASHDC
UNCLAS SECTION 01 OF 04 BRASILIA 001338
SENSITIVE
SIPDIS
DEPT PASS USTR FOR KATHERINE KALUTKIEWICZ AND TANUJA GARDE DEPT PASS USPTO
E.O. 12958: N/A
TAGS: KIPR ETRD ECON BR
SUBJECT: BRAZIL IPR UPDATE: PHARMACEUTICAL SECTOR
REF: A) BRASILIA 1175
B) Brasilia 1017
SENSITIVE BUT UNCLASSIFIED - NOT FOR DISTRIBUTION OUTSIDE USG
¶1. (SBU) SUMMARY: The Brazilian judicial and legislative branches are in the process of examining two key pharmaceutical patent-related issues - the role of the national health vigilance agency (ANVISA) in reviewing pharmaceutical patent applications and the constitutionality of Brazil's pipeline patent system. There has been no resolution of a disagreement between the Brazilian patent office (INPI) and the Inter-Ministerial Intellectual Property Group (GIPI) regarding patents for polymorphs and second uses. In addition, INPI's stated reasoning for a recent patent denial (lack of inventive step) raises potential questions about the treatment of incrementally innovative pharmaceutical patent applications - though underlying political pressure to lower costs for Brazil's AIDS program may have been at work in that case. With Brazil preparing for a major election in October 2010, it is possible that no definitive action will be taken on these topics in the near future. END SUMMARY.
JUDICIAL AND LEGISLATIVE REVIEWS OF ANVISA ROLE ------------------------------------------------------------------------------------------
¶2. (SBU) Article 229C of Law 9279/1996 (Brazil's IP Law) requires ANVISA's "prior informed consent" before a pharmaceutical patent can be approved. In an October meeting with Econoff, federal judge Liliane Roriz explained that there have been several federal court decisions in recent years regarding ANVISA's role in reviewing pharmaceutical patent applications. Two decisions in the first instance ruled against the intervention of ANVISA in patentability criteria and two ruled for it. At the appellate level, one decision (in which Judge Roriz participated) ruled against ANVISA's intervention and the other found such intervention to be legal. Judge Roriz's written opinion in the case, which she repeated to Econoff, stated that ANVISA should have, at most, a reference role in that ANVISA has more comprehensive files regarding prior art for pharmaceutical inventions.
¶3. (U) On November 6, the Brazilian attorney general (as a result of a formal request brought by the Brazilian patent office, INPI) issued an opinion (No. 210/PGF/AE/2009) ruling against ANVISA's current practice of reviewing patentability requirements. The opinion states that ANVISA has the authority to examine patent applications only with regards to a public health perspective. According to the opinion, the patentability requirements of a pharmaceutical invention can only be examined by INPI, since ANVISA's competency is limited to preventing the production and marketing of products and services potentially harmful to human health. The opinion has been presented for review to the office of the President.
¶4. (U) Separately, the Brazilian legislature is also examining ANVISA's role in reviewing pharmaceutical patent applications. Draft Law 3709 of 2008 (currently pending review by the House of Representatives' Committee on Economic Development, Industry, and Commerce) would strike from Brazil's IP law the requirement for ANVISA's prior consent on issuance of pharmaceutical patents. The written justification for Draft Law 3709 explains that Section 229C of the IP Law, where it is stated that pharmaceutical patent approval shall depend on the prior consent of ANVISA, was intended only to apply to pipeline patents - the direct subject of Sections 229-231.
¶5. (U) Brazil implemented the pipeline system as part of adopting the 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Under the pipeline system Brazil began recognizing in 1996 pharmaceutical patents that had been filed in other countries before Brazil allowed such patents. Affected patents were recognized based on the date of first foreign filing, so long as the patent was approved in a foreign country, the patent subject matter was not previously marketed in Brazil, and the application was filed within one year of the publication of the Intellectual Property Act of 1996. Such pipeline patents would expire on the date corresponding to their original foreign-issued patent or not more than 20 years from the date of their filing in Brazil.
¶6. (U) On November 10, Econoff attended a public hearing at the Brazilian Chamber of Deputies. Former Deputy Ney Lopes, who served as rapporteur for the law that introduced Section 229C, testified that the intention at the time was for the section to be limited in scope to pipeline patents. He said that the current application of Section 229C implies doubt of INPI's competency and needlessly duplicates work. Professor Aluizo Borem, representing the Brazilian National Technical Committee on Biosafety (CTNBio), emphasized the long process for creating new drugs and treatments and argued that Brazil should aim for a regulatory environment conducive to innovation. He argued that a plain reading of the IP Law shows that Section 229C applied only to pipeline patent applications and that to require ANVISA's consent on non-pipeline patents serves only to add bureaucratic steps without legal justification or benefit to society. Deputy Moreira Mendes agreed that the requirement for ANVISA's prior consent is not well-grounded in the law, nor does it recognize the separate competencies of ANVISA and INPI. In making broader comments on patents and public interest, he pointed out that generics would not exist without the breakthroughs and investments of original drug manufacturers.
¶7. (U) Celia Chaves, President of the Brazilian National Federation of Pharmacists (FENAFAR) and representing the IP Working Group of the Brazilian Network for the Integration of All People, argued that international standards and agreements confirm the primacy of public health over commercial interests. She said that Section 229C was not specific to pipeline patents and should be maintained in its entirety, since ANVISA's review is more rigorous than that of INPI and is conducted with public health in mind. She decried the "delaying strategies" of brand-name drug makers and claimed that only 15% of drugs approved by the U.S. Food and Drug Administration between 1989 and 2000 were "truly innovative." The remainder, she argued, are for things like new salt forms or polymorphs of existing molecules, which are "not that hard" to create and "do not have new therapeutic benefits." (Note: This statistic is drawn from a May 2002 report published by the U.S. National Institute for Health Care Management Research and Education. The Pharmaceutical Research and Manufacturers of America [PhRMA] issued a critique of this report noting that the referenced statistics arbitrarily exclude large numbers of medicines, specifically vaccines and biologics, and misuses the FDA's Priority Review Classification System in assessing what drugs are innovative. End note.) As for the competencies of INPI and ANVISA, Ms. Chaves interpreted that Section 101 of the IP Law, which defines the competency of INPI, does not give INPI exclusive dominion over patents.
¶8. (U) Odinir Finotti, President of the Brazilian Generic Manufacturers Association (ProGenericos), said that the generic industry wants to follow the law as it is written but that brand-name manufacturers are using deceptive strategies to extend the life of their patents, including pipeline patents. He argued that patents granted today would have no benefit for public health in Brazil until their expiration in 20 years and that Brazil is best served by maintaining ANVISA's review in order to be more cautious about the concession of patent rights.
---------------- PIPELINE PATENTS ----------------
¶9. (SBU) In April 2009, the Brazilian Attorney General submitted to the Federal Supreme Court (STF) a challenge to the constitutionality of the pipeline patent system. According to the Attorney General's submission, inventions patented under the pipeline system did not meet the requirement for novelty since they were publicly released once the patent application was submitted outside of Brazil. The STF has not yet ruled on this case. Federal Judge Roriz told Econoff that she finds the case "ridiculous" and feels that it would not make sense to declare pipeline patents unconstitutional thirteen years after the measure was implemented. It is an indication of the weakness of the case, she says, that it took so long to bring a file to the STF. 10. (U) The STF has not yet issued any opinions on the case.
-------------------- VOICES IN THE DEBATE ----------------------
¶11. (SBU) Post has reported previously (ref A) that the Ministry of Exterior Relations (MRE) and the Ministry of Health (MOH) frequently argue that IP protection is only one path (and an optional one at that) to innovation and economic development and that it must be balanced against the public interest. While the Ministry of Development, Industry, and Commerce (MDIC) has seemed more willing to consider IP protection as a key component of economic development, MDIC's Secretary of Industrial Technology Francelino Grando recently supported the MRE and MOH view during opening remarks at a November 5 seminar on IP and Innovation hosted by the Brazilian Association of Fine Chemical Industries (ABIFINA - an organization whose members include major Brazilian generic drug manufacturers like Ache, Eurofarma, and EMS). Secretary Grando stated that the GOB should resist international pressure for more concessions (i.e. TRIPS-plus) on IP and underlined the legitimacy of subordinating patent policy to the interests of economic and social development.
¶12. (U) The ABIFINA seminar was structured into three panels on the judicial, economic, and social aspects of intellectual property. The majority of the panelists focused on what they called the anti-competitive nature of pharmaceutical patents and the impact to society of decreased access to medications. One panelist, Professor Bruno van Pottelsberghe of the Free University of Brussels, focused his presentation on the factors in various patent systems that affect the quality of approved patents (which he found to be worst in the U.S. Patent and Trademark Office), but he also pointed out that pharmaceutical companies take on tremendous financial investments and risks to develop and test new drugs. Unless governments are willing to take on that role themselves, he said, they must acknowledge the public interest in access to as-yet-undeveloped medicines.
¶13. (U) Ronaldo Fiani, a professor of economics at the Federal University of Rio de Janeiro, said there are two "myths" dominating the patent conversation - the myth that patents are "good monopolies" and the myth that IP protection is an effective incentive for innovation. Professor Fiani expressed dismay that Brazil's own competition authority (CADE) has made public arguments for the benefits of the temporary monopoly granted by IP protection. He went on to say that only technical capacity-building can promote innovation and that economists invented the myth of IP protection as an incentive to innovate. Professor van Pottelsberghe responded that while some elements of the current patent system may be flawed, IP protection is not a carrot enticing a horse to run, but rather the road itself. That is, IP protection is a fundamental pre-condition for innovation and economic development.
-------------POLYMORPHS AND SECOND-USE PATENTS -----------------
¶14. (U) The December 2008 Inter-Ministerial Group on Intellectual Property (GIPI) decision against patentability of polymorphs and new medical indications of existing drugs (second-use patents) has yet to be implemented by a change in Brazil's patent law. INPI tells IPR Attach that they continue to evaluate applications on a case-by-case basis, approving patent applications that meet the patentability requirements of novelty and inventive step. Draft Law 2511 of 2007 would amend the Brazilian patent law to disallow second-use patents. The draft law has been awaiting consideration by the Brazilian House of Representatives' Committee on Economic Development, Industry, and Commerce since August 2009.
------------------------------- TENOFOVIR -------------------------------------------
¶15. (SBU) As reported previously (ref B), the case of U.S. pharmaceutical company Gilead's rejected patented application for the AIDS drug tenofovir has raised concerns about INPI's stance on patents for incrementally innovative drugs. (Note: Gilead has not yet filed a planned judicial appeal in Brazil. End note.) A patent application for the same drug was refused by the Indian patent office in September 2009, based partly on pre-grant opposition filed by the Brazilian AIDS advocacy group Brazilian Interdisciplinary AIDS Association (ABIA) in cooperation with an Indian NGO. ABIA's opposition filing stated that a patent in India would have a direct impact on the ability of Brazil to produce and access generic versions of tenofovir.
-------------------------------- COMMENT ------------------------------------------
¶16. (SBU) The issues surrounding patents for pharmaceutical products are unlikely to be resolved during the lead-up to the October 2010 elections. With the media and elite's attention focused on the campaigns for president, all 26 state governors, two-thirds of the Senate, and all federal deputies, Post expects that action in most controversial areas will be stalled until after a new government is in place in January 2011. President Lula's BRASILIA 00001338 004 OF 004 sustained popularity is largely based on his personal connection with the country's lower classes and his party (with current Presidential Chief of Staff Dilma Rousseff as its presidential candidate) will not want to jeopardize that populist touch. Given the popularly-held belief that pharmaceutical patents benefit multi-national drug companies at the expense of the Brazilian public, reforms to strengthen Brazil's patent system are not vote-winners and therefore are unlikely to be pursued over the next twelve months. END COMMENT. KUBISKE